Matteo Pedrelli

Scientist with more than 15 years of competence and experience in the field of cardiometabolic diseases, lipid and lipoprotein metabolism have been the major interest of my research since my PhD studies. I am combining excellent skills in laboratory techniques together with a great experience as public speaker, meeting organizer and project coordinator. Enthusiastic, forward-thinking and well-organized team player with an extreme attitude to adapt and improve new environment. I achieved the MSc in Drug Chemistry and Technologies in 2005 at the University of Parma, Italy, where I performed my doctoral study (2006-2008) to obtain a PhD in Experimental pharmacology and toxicology in 2009. 2008-2009 I was visiting scientist at Karolinska Institutet (Sweden), where I completed my first postdoc fellowship (2010-2014). 2014-2017 I joined AstraZeneca Med-Immune postdoc programme with a project aimed to investigate the HDL subclasses present in metabolic diseases and their capacities for mobilizing extracellular lipids. Since 2017 I have been employed as Research Coordinator at Karolinska Institutet, joining the Cardiometabolic Unit, Dept of Medicine and of Laboratory Medicine, which drives innovative and implementable research and education, closely integrated with specialized health care. I have more than 30 publications in scientific peer-reviewed journal and my research focused on a intracellular cholesterol esterifying enzyme (SOAT2) led to a patent on SOAT2-specific inhibitor PRD-family compounds, which I co-share with Kitasato University. I am steering committee member of the Lipid and Lipoprotein network at Karolinska Institutet, council member of the Scandinavian Society for Atherosclerosis Research, and co-founder and owner of Lipoprotein Research Stockholm AB. I have been lecturer for several doctoral courses and supervisor for several students. Since 2022, I'm acting as Chief Safety representative at Karolinska Institutet.